Walt A. Linscott was named Chief Operating Officer of Indaptus Therapeutics, Inc., effective June 1, 2026. As of November 8, 2026, Indaptus Therapeutics, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 3, 2026 to September 4, 2026, naming 6 appointments and 3 departures (Form 8-K, June 5, 2026).
Who owns Indaptus Therapeutics, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Indaptus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Tim Ruan · 8-K, 2026-09-04
- · In / out: In · Person: Walt A. Linscott · Role: Chief Operating Officer · Effective: 2026-06-01 · 8-K, 2026-06-05
- · In / out: In · Person: Tim Ruan · Role: Director · Effective: 2026-04-22 · 8-K/A, 2026-04-24
- · In / out: In · Person: Tim Ruan · Role: Director · Effective: 2026-04-22 · 8-K, 2026-04-23
- · In / out: In · Person: Qinglai Lu · Role: Director · Effective: 2026-04-08 · 8-K, 2026-04-03
Indaptus Therapeutics, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-03 to 2026-09-04. They name 4 people, with 6 appointments and 3 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Indaptus Therapeutics, Inc. files it.
Also on the record for Indaptus Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 22, 2026 | Stake report, Schedule 13D/A, by Dai Junyi | 7.325% of the class | 5%+ stakes | Source |
| October 22, 2026 | Stake report, Schedule 13D/A, by Sino Lion Ventures Ltd | 25.325% of the class | 5%+ stakes | Source |
| October 22, 2026 | Stake report, Schedule 13D/A, by Yao Yun | 27.34% of the class | 5%+ stakes | Source |
| October 21, 2026 | Stake report, Schedule 13D/A, by Yang Ting | 6.48% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by Dai Junyi | 8.44% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by Sino Lion Ventures Ltd | 29.19% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by Yang Ting | 8.44% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by Yao Yun | 31.51% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13D/A, by Yao Yun | 37.1% of the class | 5%+ stakes | Source |
| April 6, 2026 | Stake report, Schedule 13G/A, by YA II PN, Ltd. | — | 5%+ stakes | Source |
| March 30, 2026 | Stake report, Schedule 13D, by Yao Yun | 37.8% of the class | 5%+ stakes | Source |
| March 24, 2026 | Stake report, Schedule 13D/A, by Lazar David E. | 47.93% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Indaptus Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Indaptus Therapeutics, Inc. and the records around it.
The people at Indaptus Therapeutics, Inc.
- Hila Karah is also named on 9 other Form D filings: DarioHealth Corp. (Oct 2025)
Indaptus Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- YA II PN, Ltd. also filed stake reports on 13 other companies: Ives Ultra AI Opportunities Inc. (Oct 2026), Beneficient (Oct 2026), Optimi Health Corp. (Oct 2026)
Watch Indaptus Therapeutics, Inc.
Get an email when Indaptus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Indaptus Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Indaptus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indaptus Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-04 | Out | 8-K, 2026-09-04 | |||
| 2026-06-05 | In | Chief Operating Officer | 2026-06-01 | 8-K, 2026-06-05 | |
| 2026-04-24 | In | Director | 2026-04-22 | 8-K/A, 2026-04-24 | |
| 2026-04-24 | In | 8-K/A, 2026-04-24 | |||
| 2026-04-24 | Out | Director | 8-K/A, 2026-04-24 | ||
| 2026-04-23 | In | Director | 2026-04-22 | 8-K, 2026-04-23 | |
| 2026-04-23 | In | 8-K, 2026-04-23 | |||
| 2026-04-23 | Out | Director | 8-K, 2026-04-23 | ||
| 2026-04-03 | In | Director | 2026-04-08 | 8-K, 2026-04-03 |
Who leads Indaptus Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Walt A. Linscott, appointed, effective 2026-06-01 (filed 2026-06-05).
- Director: Matthew McMurdo, departure reported (filed 2026-04-24). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Indaptus Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Indaptus Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Indaptus Therapeutics, Inc.Every change, in the filing's words
Departing: Tim Ruan
On September 2, 2026, Tim Ruan notified the Board of Directors (the " Board ") of Indaptus Therapeutics, Inc. (the " Company ") of his resignation from the Board, effective immediately.
- Mr. Ruan's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Appointed: Walt A. Linscott, Chief Operating Officer, effective 2026-06-01
Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.
- Resignation of Directors and Officer Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the "Board") of Indaptus Therapeutics, Inc. (the "Company").
- Mr. Lazar's, Mr. Ben-Tzvi's and Mr. Linscott's resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies or practices.
- The Board wishes to thank Mr. Lazar and Mr. Ben-Tzvi for their services and contributions to the Company, and looks forward to continuing to work with Mr. Linscott in his strategic advisory role.
Appointed: Tim Ruan, Director, effective 2026-04-22
On April 17, 2026, the Board of Directors (the " Board ") of Indaptus Therapeutics, Inc. (the " Company ") appointed Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors of the Board, effective April 22, 2026.
Appointed: Tim Ruan
Committee Appointments Effective as of their respective appointment dates to the Board: Mr. Ruan was appointed to serve as a member of the Audit Committee of the Board.
Departing: Matthew McMurdo, Director
On April 22, 2026, Matthew McMurdo resigned as a director of the Company.
- Tim Ruan, 40, is a seasoned financial executive with extensive experience in capital markets, investment banking, and the biotechnology sector.
- He currently serves as the Chief Financial Officer of Ocumension Therapeutics, where he oversees financial management, risk, mergers and acquisitions, and investor relations.
- His career includes senior leadership roles at premier global financial institutions, including serving as an Executive Director at Goldman Sachs (Asia) LLC and a Vice President at Morgan Stanley Asia Limited.
- Throughout his career, Mr. Ruan has successfully executed numerous high-profile IPOs and cross-border transactions for leading healthcare and technology companies.
- He holds a Master of Science in Biotechnology from the Hong Kong University of Science and Technology and a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales.
- Johnny Fox Arrowsmith (Yi Zhang), 48, is an expert in intellectual property and life sciences, with a distinguished career spanning both law and scientific research.
- As a Partner at JunHe, he focuses on U.S.-China cross-border intellectual property matters, patent portfolio management, and freedom-to-operate analyses.
Appointed: Tim Ruan, Director, effective 2026-04-22
On April 17, 2026, the Board of Directors (the " Board ") of Indaptus Therapeutics, Inc. (the " Company ") appointed Mr. Tim Ruan and Dr. Yi Zhang as independent directors of the Board, effective April 22, 2026.
Appointed: Tim Ruan
Committee Appointments Effective as of their respective appointment dates to the Board: Mr. Ruan was appointed to serve as a member of the Audit Committee of the Board.
Departing: Matthew McMurdo, Director
On April 22, 2026, Matthew McMurdo resigned as a director of the Company.
- Tim Ruan, 40, is a seasoned financial executive with extensive experience in capital markets, investment banking, and the biotechnology sector.
- He currently serves as the Chief Financial Officer of Ocumension Therapeutics, where he oversees financial management, risk, mergers and acquisitions, and investor relations.
- His career includes senior leadership roles at premier global financial institutions, including serving as an Executive Director at Goldman Sachs (Asia) LLC and a Vice President at Morgan Stanley Asia Limited.
- Throughout his career, Mr. Ruan has successfully executed numerous high-profile IPOs and cross-border transactions for leading healthcare and technology companies.
- He holds a Master of Science in Biotechnology from the Hong Kong University of Science and Technology and a Bachelor of Commerce (Finance) and a Bachelor of Laws from the University of New South Wales.
- Yi Zhang (Johnny), 48, is an expert in intellectual property and life sciences, with a distinguished career spanning both law and scientific research.
- As a Partner at JunHe, he focuses on U.S.-China cross-border intellectual property matters, patent portfolio management, and freedom-to-operate analyses.
- Dr. Zhang has extensive experience advising on intellectual property diligence for strategic investments and mergers and acquisitions across the life sciences, chemistry, and robotics industries.
Appointed: Qinglai Lu, Director, effective 2026-04-08
On March 31, 2026, the Board of Directors appointed Qinglai Lu as a member of the Board of Directors, effective April 8, 2026.
- Resignation of Officer Nir Sassi resigned as Chief Financial Officer on April 1, 2026.
- Mr. Sassi's resignation is not based on any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The Board of Directors of the Company deemed Qinglai Lu to qualify as "independent" in accordance with the listing requirements of Nasdaq.
- Qinglai Lu, 48, brings over 20 years of experience across corporate finance, banking and debt capital markets, asset management, distressed investments, and private banking in the Asia-Pacific region.
- Mr. Lu joined Plunkett Capital in May 2019 as Managing Partner.
- His key responsibilities included structuring and arranging private credit and equity financing for corporates, while deploying proprietary capital and managed funds to invest alongside such transactions; leading the firm's proprietary investment in a regional multi-family office and serving on its board, participating in strategic decision-making and major initiatives, while building deep relationships with dozens of entrepreneurial families across Asia-Pacific; developing asset management and direct investment opportunities across Asia-Pacific, with a strategic focus on Japan and Singapore.
Tools for this story
Each opens in a new tab, filled in for Indaptus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.